A Phase 2 interventional study of Belcesiran and Placebo in Alpha 1-Antitrypsin Deficiency, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. Terminated at 23 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (part of Novo Nordisk A/S) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 39th largest by enrollment of the 55 interventional ones that give a count, is one of 2 that started in 2021, is one of 20 in phase 2, and was the 62nd registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
Tessera Therapeutics, Inc. · Sites in United States, Australia, Netherlands and 2 more countries
Ages 18–70
University of Alabama at Birmingham · Sites in United States
Ages 19+
Columbia University · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 28 · Phase 3 11 · Phase 4 4
First in 1995; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 55 interventional studies, 190 across the 26 observational. Of the 57 that completed or were terminated, 29 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 81 have an industry lead sponsor. The 10 most frequent:
This study is registered under Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, one of the names counted as Novo Nordisk A/S. Under that name alone:
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Novo Nordisk A/S has 3 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in alpha 1-Antitrypsin Deficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT05297812Columbia UniversityAlpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease | 2027-01 |
| NCT07135427University of Alabama at BirminghamGenetic Variation in IgG in Alpha 1 Antitrypsin Deficiency | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD).
The study will be conducted in 3 separate cohorts. A total of up to 16 participants may be enrolled in Cohort 1 and 2. A total number of 30 subjects will be enrolled in cohort 3. The 3 cohorts are differentiated by the duration of the treatment period, the number of doses administered, and the timing of the second liver biopsy.
AATD-associated liver disease is a progressive condition resulting in liver fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. The lack of functional alpha-1 antitrypsin (AAT) in individuals with the PiZZ genotype, in conjunction with other precipitating factors, can lead to unchecked activity of neutrophil elastases in the alveoli; causing emphysema and chronic obstructive pulmonary disease (COPD). This loss-of-function mechanism may be addressed by use of intravenous augmentation therapy, which aims to substitute the missing AAT by infusing alpha-1 proteinase inhibitor (A1PI), purified from pooled human plasma.
While augmentation therapy can address the loss of AAT in the lung, no treatment exists for the associated liver disease.
Given the severity of the disease, with approximately 10% of affected patients developing liver cirrhosis and a subgroup of those patients in need of liver transplantation, and the lack of an effective treatment that addresses the toxic hepatic "gain-of-function" mechanism, there is an urgent unmet medical need to develop a therapy that can help this particular patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Belcesiran
Other: Placebo
Drug: Belcesiran
Other: Placebo
Drug: Belcesiran
Other: Placebo
Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
Comparator: Placebo Cohort 1 Administered sterile normal saline (0.9% NaCl) matching volume of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.
Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 96 weeks.
Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Number of TEAEs and SAEs is presented. An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were defined as TEAEs if they had a start date on or after the administration of study drug during the treatment period, or if they occurred prior to the administration of study drug and worsened in severity/grade or relationship to the study intervention after the administration of study intervention during the treatment period. A SAE was defined as any untoward medical occurrence that, at any dose: a) resulted in death, b) is life-threatening, c) required inpatient hospitalization or prolongation of existing hospitalization, d) resulted in persistent disability/incapacity, e) was a congenital anomaly/birth defect.
Time frame: Up to 2.6 years
Number of Participants With TEAEs and SAEs
Number of participants with TEAEs and SAEs is presented. An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were defined as TEAEs if they had a start date on or after the administration of study drug during the treatment period, or if they occurred prior to the administration of study drug and worsened in severity/grade or relationship to the study intervention after the administration of study intervention during the treatment period. A SAE was defined as any untoward medical occurrence that, at any dose: a) resulted in death, b) is life-threatening, c) required inpatient hospitalization or prolongation of existing hospitalization, d) resulted in persistent disability/incapacity, e) was a congenital anomaly/birth defect.
Time frame: Up to 2.6 years
Change From Baseline in Pulmonary Function Tests (PFTs): Forced Vital Capacity (FVC)
Change in FVC from baseline (Day 1) to week 96 is presented. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, that is, VC performed with a maximally forced expiratory effort.
Time frame: Baseline (Day 1), week 96
Change From Baseline in PFT: Forced Expiratory Volume in One Second (FEV1)
Change in FEV1 from baseline (Day 1) to week 96 is presented. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.
Time frame: Baseline (Day 1), week 96
Change From Baseline in PFT: FEV1/FVC Ratio
Change in FEV1/FVC ratio from baseline (Day 1) to week 96 is presented. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, that is, VC performed with a maximally forced expiratory effort.
Time frame: Baseline (Day 1), week 96
Change From Baseline in PFT: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)
Change in DLCO from baseline (Day 1) to week 96 is presented. DLCO is a measure of the quantity of carbon monoxide (CO) transferred per minute from alveolar gas to red blood cells (specifically hemoglobin) in pulmonary capillaries. It is expressed as millimoles per minute per kilopascal (mmol/min/kPa).
Time frame: Baseline (Day 1), week 96
Change From Baseline in 12 -Lead Electrochardiograms (ECGs): Mean Heart Rate
Change from baseline (Day 1) to week 96 in mean heart rate is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in 12 -Lead ECGs: Mean Ventricular Rate
Change from baseline (Day 1) to week 96 in mean ventricular rate is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in 12 -Lead ECGs: PR Interval, QRS Interval, QT Interval, QTcF Interval and RR Interval
Change from baseline (Day 1) to week 96 in PR interval, QRS interval, QT interval, QTcF interval and RR interval is presented.
Time frame: Baseline (Day 1), week 96
Number of Participants With Physical Examination Findings
Number of participants with physical examination findings at week 96 is presented. The data is presented under categories:a) Normal, b) Abnormal, not clinically significant, c) Abnormal, clinically significant.
Time frame: At week 96
Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure
Change from baseline (Day 1) to week 96 in diastolic blood pressure and systolic blood pressure is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Vital Signs: Heart Rate
Change from baseline (Day 1) to week 96 in heart rate is presented.
Time frame: Baseline (Day 1), week 96
Vital Signs: Height at Baseline
Height at baseline is presented.
Time frame: Baseline (Day 1)
Change From Baseline in Vital Signs: Respiratory Rate
Change from baseline (Day 1) to week 96 in respiratory rate is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Vital Signs: Temperature
Change from baseline (Day 1) to week 96 in temperature is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Vital Signs: Weight
Change from baseline (Day 1) to week 96 in weight is presented.
Time frame: Baseline (Day 1), week 96
Change in Clinical Laboratory Tests: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Glutamate Dehydrogenase, Lactate Dehydrogenase, Biomarker Creatine Kinase (M30) and Biomarker Creatine Kinase (M65)
Change from baseline (Day 1) to week 96 in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatine kinase, glutamate dehydrogenase, lactate dehydrogenase, biomarker creatine kinase (M30) and biomarker creatine kinase (M65) is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Albumin, Apolipoprotein A1, Protein, Biomarker Haptoglobin
Change from baseline (Day 1) to week 96 in albumin, apolipoprotein A1, protein and biomarker haptoglobin is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Bilirubin, Creatinine and Direct Bilirubin
Change from baseline (Day 1) to week 96 in bilirubin, creatinine and direct bilirubin is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglycerides and Urea Nitrogen
Change from baseline (Day 1) to week 96 in chloride, cholesterol, glucose, potassium, sodium, triglycerides and urea nitrogen is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Gamma Glutamyl Transferase
Change from baseline (Day 1) to week 96 in gamma glutamyl transferase is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Basophils, Eosinophils, Leucocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Change from baseline (Day 1) to week 96 in basophils, eosinophils, leucocytes, lymphocytes, monocytes, neutrophils and platelets is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Basophils/Leucocytes
Change from baseline (Day 1) to week 96 in basophils/leucocytes is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Eosinophils/Leucocytes
Change from baseline (Day 1) to week 96 in eosinophils/leucocytes is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Haematocrit
Change from baseline (Day 1) to week 96 in haematocrit is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Lymphocytes/Leucocytes
Change from baseline (Day 1) to week 96 in lymphocytes/leucocytes is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Monocytes/Leucocytes
Change from baseline (Day 1) to week 96 in monocytes/leucocytes is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Neutrophils/Leucocytes
Change from baseline (Day 1) to week 96 in neutrophils/leucocytes is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Reticulocytes/Erythrocytes
Change from baseline (Day 1) to week 96 in reticulocytes/erythrocytes is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin Concentration and Haemoglobin
Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular haemoglobin concentration and haemoglobin is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin
Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular haemoglobin is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Volume
Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular volume is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Erythrocytes
Change from baseline (Day 1) to week 96 in erythrocytes is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Specific Gravity
Change from baseline (Day 1) to week 96 in specific gravity is reported.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Urine Erythrocytes and Urine Leucocytes
Change from baseline (Day 1) to week 96 in urine erythrocytes and urine leucocytes is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Potential of Hydrogen (pH)
Change from baseline (Day 1) to week 96 in pH is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Activated Partial Thromboplastin Time and Prothrombin Time
Change from baseline (Day 1) to week 96 in activated partial thromboplastin time and prothrombin time is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Prothrombin International Normalized Ratio
Change from baseline (Day 1) to week 96 in prothrombin international normalized ratio is presented.
Time frame: Baseline (Day 1), week 96
Change in Clinical Laboratory Tests: Alpha Fetoprotein, Biomarker Hyaluronic Acid, Biomarker Matrix Metalloproteinase 9, Biomarker Procollagen 3 N-Terminal Propeptide, Biomarker Tissue Inhibitor of Metalloproteinase 1, Complement C3a and Complement C5a
Change from baseline (Day 1) to week 96 in alpha fetoprotein, biomarker hyaluronic acid, biomarker matrix metalloproteinase 9, biomarker procollagen 3 N-Terminal propeptide, biomarker tissue inhibitor of metalloproteinase 1, complement C3a and complement C5a is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: C-Reactive Protein
Change from baseline (Day 1) to week 96 in C-reactive protein is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Complement Bb
Change from baseline (Day 1) to week 96 in complement Bb is presented.
Time frame: Baseline (Day 1), week 96
Change From Baseline in Clinical Laboratory Tests: Complement Total (CH50)
Change from baseline (Day 1) to week 96 in CH50 is presented.
Time frame: Baseline (Day 1), week 96
Cohort 1: Change From Baseline in Serum Alpha-1 Antitrypsin (AAT) Protein Concentrations
Change from baseline (Day 1) to week 24 in serum AAT protein concentrations in Cohort 1 is presented.
Time frame: Baseline (Day 1), week 24
Cohort 2: Change From Baseline in Serum AAT Protein Concentrations
Change from baseline (Day 1) to week 48 in serum AAT protein concentrations in Cohort 2 is presented.
Time frame: Baseline (Day 1), week 48
Change From Baseline in Liver Fibrosis Ishak Score
Change from Baseline up until week 48 in liver fibrosis based on Ishak score is presented. The Ishak staging system for liver fibrosis is a 1995 update to the algorithm initially developed by De Groote et al. Ishak scores range from 0 (no fibrosis) to 6 (cirrhosis) which are as follows: 0-no fibrosis, 1-fibrous expansion of some portal areas, with or without short fibrous septa, 2-Fibrous expansion of most portal areas, with or without short fibrous septa, 3-Fibrous expansion of most portal areas with occasional portal-to-portal bridging, 4-Fibrous expansion of portal areas with marked bridging (portal to portal as well as portal to central), 5-Marked bridging (portal-portal and/or portal-central) with occasional nodules (incomplete cirrhosis), 6-Cirrhosis, probable or definite.
Time frame: Baseline (Day 1), week 48
The trial was conducted at 8 sites in 8 countries. The number of sites that randomised participants are as follows: Australia (1), Belgium (1), Germany (1), Netherlands (1), New zealand (1), Portugal (1), Spain (1) and United states of America (1).
| Milestone | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Started | 5 | 5 | 6 |
| Safety population | 5 | 5 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 5 | 5 | 6 |
| Withdrew: Study terminated by sponsor | 2 | 2 | 5 |
| Withdrew: Withdrawal by subject | 3 | 3 | 1 |
Number of TEAEs and SAEs is presented. An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were defined as TEAEs if they had a start date on or after the administration of study drug during the treatment period, or if they occurred prior to the administration of study drug and worsened in severity/grade or relationship to the study intervention after the administration of study intervention during the treatment period. A SAE was defined as any untoward medical occurrence that, at any dose: a) resulted in death, b) is life-threatening, c) required inpatient hospitalization or prolongation of existing hospitalization, d) resulted in persistent disability/incapacity, e) was a congenital anomaly/birth defect.
| Events | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| TEAE | 27 | 80 | 43 |
| SAE | 0 | 7 | 5 |
Number of participants with TEAEs and SAEs is presented. An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were defined as TEAEs if they had a start date on or after the administration of study drug during the treatment period, or if they occurred prior to the administration of study drug and worsened in severity/grade or relationship to the study intervention after the administration of study intervention during the treatment period. A SAE was defined as any untoward medical occurrence that, at any dose: a) resulted in death, b) is life-threatening, c) required inpatient hospitalization or prolongation of existing hospitalization, d) resulted in persistent disability/incapacity, e) was a congenital anomaly/birth defect.
| Participants | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| TEAE | 5 | 5 | 5 |
| SAE | 0 | 2 | 2 |
Change in FVC from baseline (Day 1) to week 96 is presented. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, that is, VC performed with a maximally forced expiratory effort.
| Liters (L) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Pulmonary Function Tests (PFTs): Forced Vital Capacity (FVC) | -0.410 | -0.250 ± 0.0424 | — |
Change in FEV1 from baseline (Day 1) to week 96 is presented. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.
| L | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in PFT: Forced Expiratory Volume in One Second (FEV1) | -0.210 | -0.290 ± 0.2263 | — |
Change in FEV1/FVC ratio from baseline (Day 1) to week 96 is presented. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, that is, VC performed with a maximally forced expiratory effort.
| Ratio of FEV1/FVC | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in PFT: FEV1/FVC Ratio | 0.020 | -0.055 ± 0.0778 | — |
Change in DLCO from baseline (Day 1) to week 96 is presented. DLCO is a measure of the quantity of carbon monoxide (CO) transferred per minute from alveolar gas to red blood cells (specifically hemoglobin) in pulmonary capillaries. It is expressed as millimoles per minute per kilopascal (mmol/min/kPa).
| mmol/min/kPa | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in PFT: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) | -1.89497 | -1.01110 ± 0.146774 | — |
Change from baseline (Day 1) to week 96 in mean heart rate is presented.
| beats per minute | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in 12 -Lead Electrochardiograms (ECGs): Mean Heart Rate | -10.0 | 1.0 | — |
Change from baseline (Day 1) to week 96 in mean ventricular rate is presented.
| beats per minute | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in 12 -Lead ECGs: Mean Ventricular Rate | -10.0 | 1.0 | — |
Change from baseline (Day 1) to week 96 in PR interval, QRS interval, QT interval, QTcF interval and RR interval is presented.
| millisecond (msec) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| PR interval | -4.0 | — | — |
| QRS interval | 10.0 | 21.0 | — |
| QT interval | 26.0 | 17.0 | — |
| QTcF interval | -1.0 | 21.0 | — |
| RR interval | 224.0 | -8.0 | — |
Number of participants with physical examination findings at week 96 is presented. The data is presented under categories:a) Normal, b) Abnormal, not clinically significant, c) Abnormal, clinically significant.
| Participants | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Normal | 1 | 1 | 0 |
| Abnormal, not clinically significant | 0 | 1 | 0 |
| Abnormal, clinically significant | 0 | 0 | 0 |
Change from baseline (Day 1) to week 96 in diastolic blood pressure and systolic blood pressure is presented.
| millimeters of mercury (mmHg) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Diastolic blood pressure | 2.0 | 17.0 | — |
| Systolic blood pressure | 13.0 | 5.0 | — |
Change from baseline (Day 1) to week 96 in heart rate is presented.
| beats per minute | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Vital Signs: Heart Rate | 1.0 | 21.0 | — |
Height at baseline is presented.
| Centimeter (cm) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Vital Signs: Height at Baseline | 178.0 ± 11.07 | 167.8 ± 9.93 | 173.0 ± 13.48 |
Change from baseline (Day 1) to week 96 in respiratory rate is presented.
| breaths per minute | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Vital Signs: Respiratory Rate | 5.0 | 1.0 | — |
Change from baseline (Day 1) to week 96 in temperature is presented.
| Degree celsius | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Vital Signs: Temperature | 0.30 | -0.40 | — |
Change from baseline (Day 1) to week 96 in weight is presented.
| kilograms (kg) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Vital Signs: Weight | 10.70 | 0.20 | — |
Change from baseline (Day 1) to week 96 in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatine kinase, glutamate dehydrogenase, lactate dehydrogenase, biomarker creatine kinase (M30) and biomarker creatine kinase (M65) is presented.
| Units per liter (U/L) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Alanine aminotransferase | -8.0 | -10.5 ± 7.78 | — |
| Alkaline phosphatase | 26.0 | 0.0 ± 29.70 | — |
| Aspartate aminotransferase | -5.0 | -10.5 ± 6.36 | — |
| Creatine kinase | -226.0 | -3.0 ± 8.49 | — |
| Glutamate dehydrogenase | 0.0 | -4.5 ± 0.71 | — |
| Lactate dehydrogenase | — | 0.5 ± 19.09 | — |
| Biomarker creatine Kinase (M30) | — | -149.5 ± 210.01 | — |
| Biomarker creatine kinase (M65) | — | -166.180 ± 329.3703 | — |
Change from baseline (Day 1) to week 96 in albumin, apolipoprotein A1, protein and biomarker haptoglobin is presented.
| Grams per liter (g/L) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Albumin | -1.0 | 3.5 ± 0.71 | — |
| Apolipoprotein A1 | -0.030 | 0.180 ± 0.1838 | — |
| Protein | -2.0 | 7.5 ± 7.78 | — |
| Biomarker haptoglobin | — | -0.260 | — |
Change from baseline (Day 1) to week 96 in bilirubin, creatinine and direct bilirubin is presented.
| Micromoles per liter (umol/L) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Bilirubin | 1.710 | 3.420 ± 0.0000 | — |
| Creatinine | 1.7680 | 22.5420 ± 19.37755 | — |
| Direct bilirubin | 0.000 | 0.000 ± 0.000 | — |
Change from baseline (Day 1) to week 96 in chloride, cholesterol, glucose, potassium, sodium, triglycerides and urea nitrogen is presented.
| Millimoles per liter (mmol/L) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Chloride | -2.0 | -1.5 ± 6.36 | — |
| Cholesterol | -0.12950 | 0.67340 ± 0.842447 | — |
| Glucose | 0.88800 | 0.55500 ± 0.078489 | — |
| Potassium | -0.60 | 0.40 ± 0.283 | — |
| Sodium | -2.0 | -0.5 ± 0.71 | — |
| Triglycerides | -0.01130 | 0.44070 ± 0.399515 | — |
| Urea nitrogen | 0.0000 | 2.4990 ± 1.00975 | — |
Change from baseline (Day 1) to week 96 in gamma glutamyl transferase is presented.
| International units per liter (IU/L) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Gamma Glutamyl Transferase | -5.0 | -30.5 ± 24.75 | — |
Change from baseline (Day 1) to week 96 in basophils, eosinophils, leucocytes, lymphocytes, monocytes, neutrophils and platelets is presented.
| 10^9 cells/liter | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Basophils | -0.020 | 0.000 ± 0.0141 | — |
| Eosinophils | -0.030 | -0.020 ± 0.0424 | — |
| Leucocytes | -1.650 | -0.600 ± 1.1455 | — |
| Lymphocytes | 0.310 | -0.130 ± 0.0849 | — |
| Monocytes | -0.010 | -0.055 ± 0.4738 | — |
| Neutrophils | -1.910 | -0.380 ± 0.5657 | — |
| Platelets | -39.0 | 1.0 ± 16.97 | — |
Change from baseline (Day 1) to week 96 in basophils/leucocytes is presented.
| Percentage of basophils/leucocytes | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Basophils/Leucocytes | -0.10 | 0.10 ± 0.424 | — |
Change from baseline (Day 1) to week 96 in eosinophils/leucocytes is presented.
| Percentage of eosinophils/leucocytes | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Eosinophils/Leucocytes | 0.20 | -0.05 ± 0.212 | — |
Change from baseline (Day 1) to week 96 in haematocrit is presented.
| Percentage of haematocrit | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Haematocrit | 0.0 | 2.5 ± 2.12 | — |
Change from baseline (Day 1) to week 96 in lymphocytes/leucocytes is presented.
| Percentage of lymphocytes/leucocytes | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Lymphocytes/Leucocytes | 17.30 | 0.85 ± 4.031 | — |
Change from baseline (Day 1) to week 96 in monocytes/leucocytes is presented.
| Percentage of monocytes/leucocytes | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Monocytes/Leucocytes | 1.20 | -0.50 ± 6.081 | — |
Change from baseline (Day 1) to week 96 in neutrophils/leucocytes is presented.
| Percentage of neutrophils/leucocytes | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Neutrophils/Leucocytes | -18.70 | -0.40 ± 1.838 | — |
Change from baseline (Day 1) to week 96 in reticulocytes/erythrocytes is presented.
| Percentage of reticulocytes/erythrocytes | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Reticulocytes/Erythrocytes | -0.80 | 0.30 ± 0.141 | — |
Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular haemoglobin concentration and haemoglobin is presented.
| g/L | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Erythrocyte mean corpuscular haemoglobin concentration | -10.0 | 0.0 ± 0.0 | — |
| Haemoglobin | -6.0 | 9.0 ± 4.24 | — |
Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular haemoglobin is presented.
| picograms (pg) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin | -1.0 | 0.5 ± 0.71 | — |
Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular volume is presented.
| femtoliter (fL) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Volume | 2.0 | 2.5 ± 0.71 | — |
Change from baseline (Day 1) to week 96 in erythrocytes is presented.
| 10^12 cells/liter | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Erythrocytes | -0.10 | 0.20 ± 0.141 | — |
Change from baseline (Day 1) to week 96 in specific gravity is reported.
| Ratio | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Specific Gravity | -0.0050 | 0.0025 ± 0.01061 | — |
Change from baseline (Day 1) to week 96 in urine erythrocytes and urine leucocytes is presented.
| per high power field (/HPF) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Urine erythrocytes | — | 3.0 | — |
| Urine leucocytes | — | 0.0 | — |
Change from baseline (Day 1) to week 96 in pH is presented.
| pH | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Potential of Hydrogen (pH) | 0.00 | -0.75 ± 1.061 | — |
Change from baseline (Day 1) to week 96 in activated partial thromboplastin time and prothrombin time is presented.
| seconds (sec) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Activated partial thromboplastin time | 0.40 | 1.55 ± 2.333 | — |
| Prothrombin time | -0.50 | 0.40 ± 0.990 | — |
Change from baseline (Day 1) to week 96 in prothrombin international normalized ratio is presented.
| Ratio | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Prothrombin International Normalized Ratio | 0.00 | 0.00 ± 0.141 | — |
Change from baseline (Day 1) to week 96 in alpha fetoprotein, biomarker hyaluronic acid, biomarker matrix metalloproteinase 9, biomarker procollagen 3 N-Terminal propeptide, biomarker tissue inhibitor of metalloproteinase 1, complement C3a and complement C5a is presented.
| nanograms per milliter (ng/mL) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Alpha fetoprotein | 0.30 | 2.90 ± 2.687 | — |
| Biomarker hyaluronic acid | — | 137.305 ± 310.3704 | — |
| Biomarker matrix metalloproteinase 9 | — | -193.65 ± 239.356 | — |
| Biomarker procollagen 3 N-terminal propeptide | — | -0.655 ± 0.5020 | — |
| Biomarker tissue inhibitor of metalloproteinase 1 | — | -83.25 ± 8.980 | — |
| Complement C3a | 139.70 | -5.60 ± 5.657 | — |
| Complement C5a | 1.890 | -1.785 ± 0.6152 | — |
Change from baseline (Day 1) to week 96 in C-reactive protein is presented.
| mg/L | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: C-Reactive Protein | 4.30 | -0.30 ± 0.849 | — |
Change from baseline (Day 1) to week 96 in complement Bb is presented.
| microgram per milliliter (ug/mL) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Complement Bb | 0.240 | 0.325 ± 0.2616 | — |
Change from baseline (Day 1) to week 96 in CH50 is presented.
| equivalent unit per milliliter (U Eq/mL) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Clinical Laboratory Tests: Complement Total (CH50) | 6.530 | -46.900 ± 40.1071 | — |
Change from baseline (Day 1) to week 24 in serum AAT protein concentrations in Cohort 1 is presented.
| g/L | Cohort 1: Belcesiran |
|---|---|
| Cohort 1: Change From Baseline in Serum Alpha-1 Antitrypsin (AAT) Protein Concentrations | -0.30 ± 0.120 |
Change from baseline (Day 1) to week 48 in serum AAT protein concentrations in Cohort 2 is presented.
| g/L | Cohort 2: Belcesiran |
|---|---|
| Cohort 2: Change From Baseline in Serum AAT Protein Concentrations | -0.50 ± 0.094 |
Change from Baseline up until week 48 in liver fibrosis based on Ishak score is presented. The Ishak staging system for liver fibrosis is a 1995 update to the algorithm initially developed by De Groote et al. Ishak scores range from 0 (no fibrosis) to 6 (cirrhosis) which are as follows: 0-no fibrosis, 1-fibrous expansion of some portal areas, with or without short fibrous septa, 2-Fibrous expansion of most portal areas, with or without short fibrous septa, 3-Fibrous expansion of most portal areas with occasional portal-to-portal bridging, 4-Fibrous expansion of portal areas with marked bridging (portal to portal as well as portal to central), 5-Marked bridging (portal-portal and/or portal-central) with occasional nodules (incomplete cirrhosis), 6-Cirrhosis, probable or definite.
| unit on a score | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Change From Baseline in Liver Fibrosis Ishak Score | 1.0 | — | -1.0 ± 0.00 |
Collected over Up to 2.6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pooled Placebo | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Cohort 1: Belcesiran | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Cohort 2: Belcesiran | 0/6 (0%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Event | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/5 | 1/5 | 0/6 |
| PneumoniaInfections and infestations | 0/5 | 1/5 | 0/6 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/5 | 1/5 | 0/6 |
| Hepatic encephalopathyNervous system disorders | 0/5 | 1/5 | 0/6 |
| DepressionPsychiatric disorders | 0/5 | 1/5 | 0/6 |
| Acute myocardial infarctionCardiac disorders | 0/5 | 0/5 | 1/6 |
| ErysipelasInfections and infestations | 0/5 | 0/5 | 1/6 |
| Viral infectionInfections and infestations | 0/5 | 0/5 | 1/6 |
| Hepatic function abnormalHepatobiliary disorders | 0/5 | 0/5 | 1/6 |
| Pulmonary function test decreasedInvestigations | 0/5 | 0/5 | 1/6 |
| Event | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran |
|---|---|---|---|
| Crystal urine presentInvestigations | 1/5 | 2/5 | 0/6 |
| HeadacheNervous system disorders | 0/5 | 2/5 | 0/6 |
| COVID-19Infections and infestations | 0/5 | 1/5 | 2/6 |
| Upper respiratory tract infectionInfections and infestations | 0/5 | 1/5 | 2/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/5 | 1/5 | 2/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/5 | 0/5 | 2/6 |
| BronchitisInfections and infestations | 0/5 | 1/5 | 1/6 |
| PneumoniaInfections and infestations | 0/5 | 1/5 | 0/6 |
| Asymptomatic bacteriuriaInfections and infestations | 0/5 | 1/5 | 0/6 |
| CystitisInfections and infestations | 0/5 | 1/5 | 0/6 |
Safety Population is defined as all participants randomly assigned to study intervention who had received at least 1 dose of the study drug (belcesiran or placebo).
| Age, Continuous(Years) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran | Total |
|---|---|---|---|---|
| Mean | 40.2 ± 17.31 | 57.2 ± 10.18 | 52.5 ± 11.86 | 50.1 ± 14.36 |
| Sex: Female, Male(Participants) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran | Total |
|---|---|---|---|---|
| Female | 1 | 3 | 2 | 6 |
| Male | 4 | 2 | 4 | 10 |
| Race/Ethnicity, Customized(Participants) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran | Total |
|---|---|---|---|---|
| White | 5 | 5 | 6 | 16 |
| Race/Ethnicity, Customized(Participants) | Pooled Placebo | Cohort 1: Belcesiran | Cohort 2: Belcesiran | Total |
|---|---|---|---|---|
| Not Hispanic or Latino | 5 | 5 | 6 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2021 to primary completion in Dec 2023, 33 months.
Results were first posted in Dec 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belcesiran
alpha 1-Antitrypsin Deficiency →
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company →